Business Wire

CGTN

11.6.2020 05:37:05 CEST | Business Wire | Press release

Share
CGTN: How China's Top-down Command System Helped Contain COVID-19?

China’s centralized and efficient command system formed a strong guarantee for the country to win the all-out people's war against COVID-19, according to a recently-released government white paper.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005922/en/

The document released on June 7 chronicled China's battle against COVID-19, detailing its painstaking yet effective efforts to control the outbreak domestically and its swift responses to contain the spread globally.

The coronavirus caught China unaware, the white paper noted, but the Chinese government acted swiftly to fight the virus and provide medical treatment for patients, prioritizing people's lives and health.

Since the first cases were detected in late December 2019, China has adopted thorough, rigorous and comprehensive prevention and control measures, as well as enforced quarantine and isolation, on a scale never seen before.

Medical resources have been mobilized across the country, and all those in need have been tested, quarantined, hospitalized or treated. With these measures in place, the country was able to contain the outbreak quickly and prevent a wider spread.

The white paper divides China's fight against the epidemic into five stages – "swift response" (December 27, 2019 to January 19, 2020), "initial containment" (January 20 to February 20), "single-digit increase in new domestic cases" (February 21 to March 17), "initial victory in a critical battle" (March 18 to April 28) and "epidemic control, new normal" (from April 29 onwards).

Timeline: China's fight against COVID-19 in five stages

Graphics: Inside China's all-out effort to contain the coronavirus

It took China more than three months to declare an initial victory in the COVID-19 battle, according to the white paper. This was possible as a result of the country's centralized and highly efficient command system, the white paper concluded.

Under the strong leadership of the CPC Central Committee with Xi Jinping at its core, central authorities exercise overall command while local authorities and all sectors follow the leadership and instructions of the central authorities, perform their respective duties and cooperate with each other.

President Xi assumed full command over the control efforts from the beginning of the outbreak. He chaired 14 meetings of the Standing Committee of the Political Bureau of the CPC Central Committee, four meetings of the Political Bureau, meetings of the Central Commission for Law-based Governance, Central Cyberspace Affairs Commission, Central Commission for Further Reform, and Central Commission for Foreign Affairs, and a meeting with prominent non-CPC figures. At these meetings, he heard briefings about epidemic prevention and control work and made decisions on overall plans for strengthening control efforts and international cooperation.

The president inspected community response and COVID-19 research in Beijing, and visited Wuhan to guide the frontline response. He has also inspected Zhejiang, Shaanxi, Shanxi and Gansu provinces, where he was briefed on progress in coordinating epidemic prevention and control with economic and social development, as well as in poverty alleviation.

Meanwhile, the central government coordinated the epidemic control work. Premier Li Keqiang, as head of the Central Leading Group for Novel Coronavirus Prevention and Control, chaired more than 30 meetings regarding COVID-19 control and economic resumption.

On January 7, Xi issued instructions on epidemic prevention and control work when he chaired a meeting of the Standing Committee of the Political Bureau of the CPC Central Committee.

On January 23, Wuhan, a megacity with a population of more than 10 million, was locked down in an unprecedented effort to contain the spread of the virus.

The central government mobilized medical experts and supplies as well as provisions for daily living needs such as food and energy to assist Wuhan and Hubei, and major public health emergency responses were activated across the country.

On January 25, the Standing Committee of the Political Bureau of the CPC Central Committee set up a central leading group on the epidemic, dispatched a central guiding team and demanded a State Council inter-agency task force play a full role in coordination.

The central leading group went to Wuhan to inspect and direct prevention and control of COVID-19 on January 27. Premier Li, who headed the leading group, also went to Wuhan to inspect the front lines.

In meetings with the CPC's senior leaders in early February, Xi called for measures to implement higher admission and treatment rates and lower infection and fatality rates. He also asked governments at all levels to implement targeted policies to contain the outbreak quickly.

Official data showed that many provinces started to lower their major public health emergency response levels from February 21, indicating the COVID-19 outbreak was coming under control.

On March 11, daily new domestic cases fell to single digits for the first time on the Chinese mainland. A week later, the mainland reported no increase in domestic cases for the first time.

As China declared an early victory in the containment of COVID-19 and normalized epidemic prevention and control, the CPC's top leadership made arrangements to steadily lift the travel restrictions and open up economic activity.

On May 7, the central government issued guidelines on normalized epidemic prevention and control.

Link:

ClickThru

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye